{"id":69693,"date":"2026-07-09T21:22:33","date_gmt":"2026-07-09T13:22:33","guid":{"rendered":"https:\/\/flcube.com\/?p=69693"},"modified":"2026-07-09T21:22:34","modified_gmt":"2026-07-09T13:22:34","slug":"jiangsu-aidea-pharmaceutical-receives-nmpa-clinical-trial-approval-for-adc119-chinas-first-domestic-complete-hiv-regimen-combining-novel-nnrti-with-established-nrtis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69693","title":{"rendered":"Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China&#8217;s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jiangsu Aidea Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688488:SHA\">SHA: 688488<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted approval to initiate clinical trials for <strong>ADC119<\/strong>, a <strong>Category 2.3 anti-HIV fixed-dose combination<\/strong> product. ADC119 represents China&#8217;s first domestically developed complete HIV treatment regimen, combining Aidea&#8217;s novel <strong>Category 1 NNRTI ainovirin (ANV)<\/strong> with established <strong>nucleoside reverse transcriptase inhibitors (NRTIs) emtricitabine (FTC)<\/strong> and <strong>tenofovir alafenamide (TAF)<\/strong> for treatment-na\u00efve adult patients with HIV-1 infection.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-product-profile\" class=\"wp-block-heading\">Regulatory Milestone &amp; Product Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Developer<\/strong><\/td><td>Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>Clinical trial approval granted by NMPA<\/td><\/tr><tr><td><strong>Product Classification<\/strong><\/td><td>Category 2.3 anti-HIV drug (China NMPA classification)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Treatment-na\u00efve adult patients with HIV-1 infection<\/td><\/tr><tr><td><strong>Dosage Form<\/strong><\/td><td>Fixed-dose combination tablet<\/td><\/tr><tr><td><strong>Active Ingredients<\/strong><\/td><td>Ainovirin (ANV) + Emtricitabine (FTC) + Tenofovir Alafenamide (TAF)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-therapeutic-innovation-amp-clinical-rationale\" class=\"wp-block-heading\">Therapeutic Innovation &amp; Clinical Rationale<\/h2>\n\n\n\n<h3 id=\"h-component-breakdown\" class=\"wp-block-heading\">Component Breakdown<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ainovirin (ANV):<\/strong> First domestic Category 1 oral anti-HIV new drug in China; non-nucleoside reverse transcriptase inhibitor (NNRTI)<\/li>\n\n\n\n<li><strong>Emtricitabine (FTC):<\/strong> Well-established NRTI with proven efficacy and safety profile<\/li>\n\n\n\n<li><strong>Tenofovir Alafenamide (TAF):<\/strong> Next-generation NRTI with improved renal and bone safety compared to tenofovir disoproxil fumarate (TDF)<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-strategic-advantages\" class=\"wp-block-heading\">Strategic Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Complete Regimen:<\/strong> Single-tablet solution eliminating need for multiple prescriptions<\/li>\n\n\n\n<li><strong>Domestic Innovation:<\/strong> Reduces China&#8217;s dependence on imported HIV therapeutics<\/li>\n\n\n\n<li><strong>Optimized Safety:<\/strong> TAF component provides enhanced safety profile over older tenofovir formulations<\/li>\n\n\n\n<li><strong>Treatment Simplification:<\/strong> Once-daily dosing improves patient adherence and treatment outcomes<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-strategic-significance\" class=\"wp-block-heading\">Market Context &amp; Strategic Significance<\/h2>\n\n\n\n<h3 id=\"h-china-hiv-treatment-landscape\" class=\"wp-block-heading\">China HIV Treatment Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population:<\/strong> Estimated 1.2 million people living with HIV in China as of 2026<\/li>\n\n\n\n<li><strong>Treatment Gap:<\/strong> Significant portion still relies on imported antiretroviral therapies<\/li>\n\n\n\n<li><strong>Policy Support:<\/strong> National emphasis on domestic pharmaceutical innovation for critical disease areas<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-positioning\" class=\"wp-block-heading\">Competitive Positioning<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Advantage:<\/strong> Only domestic complete HIV regimen in Chinese development pipeline<\/li>\n\n\n\n<li><strong>Cost Accessibility:<\/strong> Potential for significantly lower pricing compared to imported triple-combination therapies<\/li>\n\n\n\n<li><strong>Supply Chain Security:<\/strong> Domestic manufacturing reduces import dependency and supply chain risks<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-strategy-amp-commercial-implications\" class=\"wp-block-heading\">Development Strategy &amp; Commercial Implications<\/h2>\n\n\n\n<h3 id=\"h-clinical-development-pathway\" class=\"wp-block-heading\">Clinical Development Pathway<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase 1\/2 Trials:<\/strong> Initial safety, pharmacokinetics, and dose-finding studies<\/li>\n\n\n\n<li><strong>Phase 3 Pivotal Trial:<\/strong> Head-to-head comparison with standard-of-care regimens<\/li>\n\n\n\n<li><strong>Regulatory Strategy:<\/strong> Leveraging Category 2.3 classification for expedited review pathways<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-commercial-outlook\" class=\"wp-block-heading\">Commercial Outlook<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Access:<\/strong> Strong potential for inclusion in national HIV treatment guidelines<\/li>\n\n\n\n<li><strong>Reimbursement:<\/strong> High likelihood of National Reimbursement Drug List (NRDL) inclusion given public health importance<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Estimated peak annual sales of \u00a5800 million-\u00a51.5 billion ($110-210 million) in Chinese market alone<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-impact-for-jiangsu-aidea\" class=\"wp-block-heading\">Strategic Impact for Jiangsu Aidea<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This clinical trial approval marks a transformative milestone for Jiangsu Aidea, establishing the company as China&#8217;s leader in domestic HIV therapeutic development. The successful integration of their proprietary ANV molecule with established NRTIs demonstrates sophisticated combination therapy expertise and positions Aidea to capture significant market share in China&#8217;s growing HIV treatment market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The ADC119 program also validates Aidea&#8217;s broader antiviral platform, potentially enabling future expansion into other viral indications and combination regimens leveraging their NNRTI expertise.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development timelines, and market opportunities. Actual results may differ materially due to clinical trial outcomes, regulatory requirements, competitive dynamics, and other risk factors inherent in pharmaceutical development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688488_20260709_9XNW.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688488_20260709_9XNW.\"><\/object><a id=\"wp-block-file--media-210b3fd0-9be4-4f11-900b-390256efb890\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688488_20260709_9XNW.pdf\">688488_20260709_9XNW<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688488_20260709_9XNW.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-210b3fd0-9be4-4f11-900b-390256efb890\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) announced that China&#8217;s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[619,988],"class_list":["post-69693","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-aidea-pharmaceutical","tag-sha-688488"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China&#039;s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) announced that China&#039;s National Medical Products Administration (NMPA) has granted approval to initiate clinical trials for ADC119, a Category 2.3 anti-HIV fixed-dose combination product. ADC119 represents China&#039;s first domestically developed complete HIV treatment regimen, combining Aidea&#039;s novel Category 1 NNRTI ainovirin (ANV) with established nucleoside reverse transcriptase inhibitors (NRTIs) emtricitabine (FTC) and tenofovir alafenamide (TAF) for treatment-na\u00efve adult patients with HIV-1 infection.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69693\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China&#039;s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) announced that China&#039;s National Medical Products Administration (NMPA) has granted approval to initiate clinical trials for ADC119, a Category 2.3 anti-HIV fixed-dose combination product. ADC119 represents China&#039;s first domestically developed complete HIV treatment regimen, combining Aidea&#039;s novel Category 1 NNRTI ainovirin (ANV) with established nucleoside reverse transcriptase inhibitors (NRTIs) emtricitabine (FTC) and tenofovir alafenamide (TAF) for treatment-na\u00efve adult patients with HIV-1 infection.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69693\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-09T13:22:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-09T13:22:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69693#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69693\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China&#8217;s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs\",\"datePublished\":\"2026-07-09T13:22:33+00:00\",\"dateModified\":\"2026-07-09T13:22:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69693\"},\"wordCount\":522,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Aidea Pharmaceutical\",\"SHA: 688488\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69693#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69693\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69693\",\"name\":\"Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China's First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-09T13:22:33+00:00\",\"dateModified\":\"2026-07-09T13:22:34+00:00\",\"description\":\"Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) announced that China's National Medical Products Administration (NMPA) has granted approval to initiate clinical trials for ADC119, a Category 2.3 anti-HIV fixed-dose combination product. ADC119 represents China's first domestically developed complete HIV treatment regimen, combining Aidea's novel Category 1 NNRTI ainovirin (ANV) with established nucleoside reverse transcriptase inhibitors (NRTIs) emtricitabine (FTC) and tenofovir alafenamide (TAF) for treatment-na\u00efve adult patients with HIV-1 infection.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69693#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69693\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69693#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China&#8217;s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China's First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) announced that China's National Medical Products Administration (NMPA) has granted approval to initiate clinical trials for ADC119, a Category 2.3 anti-HIV fixed-dose combination product. ADC119 represents China's first domestically developed complete HIV treatment regimen, combining Aidea's novel Category 1 NNRTI ainovirin (ANV) with established nucleoside reverse transcriptase inhibitors (NRTIs) emtricitabine (FTC) and tenofovir alafenamide (TAF) for treatment-na\u00efve adult patients with HIV-1 infection.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69693","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China's First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs","og_description":"Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) announced that China's National Medical Products Administration (NMPA) has granted approval to initiate clinical trials for ADC119, a Category 2.3 anti-HIV fixed-dose combination product. ADC119 represents China's first domestically developed complete HIV treatment regimen, combining Aidea's novel Category 1 NNRTI ainovirin (ANV) with established nucleoside reverse transcriptase inhibitors (NRTIs) emtricitabine (FTC) and tenofovir alafenamide (TAF) for treatment-na\u00efve adult patients with HIV-1 infection.","og_url":"https:\/\/flcube.com\/?p=69693","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-09T13:22:33+00:00","article_modified_time":"2026-07-09T13:22:34+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69693#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69693"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China&#8217;s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs","datePublished":"2026-07-09T13:22:33+00:00","dateModified":"2026-07-09T13:22:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69693"},"wordCount":522,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Aidea Pharmaceutical","SHA: 688488"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69693#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69693","url":"https:\/\/flcube.com\/?p=69693","name":"Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China's First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-09T13:22:33+00:00","dateModified":"2026-07-09T13:22:34+00:00","description":"Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) announced that China's National Medical Products Administration (NMPA) has granted approval to initiate clinical trials for ADC119, a Category 2.3 anti-HIV fixed-dose combination product. ADC119 represents China's first domestically developed complete HIV treatment regimen, combining Aidea's novel Category 1 NNRTI ainovirin (ANV) with established nucleoside reverse transcriptase inhibitors (NRTIs) emtricitabine (FTC) and tenofovir alafenamide (TAF) for treatment-na\u00efve adult patients with HIV-1 infection.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69693#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69693"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69693#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China&#8217;s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69693"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69693\/revisions"}],"predecessor-version":[{"id":69695,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69693\/revisions\/69695"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}